277 related articles for article (PubMed ID: 18545997)
1. Cisplatin sensitivity of oral squamous carcinoma cells is regulated by Na+,K+-ATPase activity rather than copper-transporting P-type ATPases, ATP7A and ATP7B.
Ahmed Z; Deyama Y; Yoshimura Y; Suzuki K
Cancer Chemother Pharmacol; 2009 Mar; 63(4):643-50. PubMed ID: 18545997
[TBL] [Abstract][Full Text] [Related]
2. Copper efflux transporter (ATP7B) contributes to the acquisition of cisplatin-resistance in human oral squamous cell lines.
Yoshizawa K; Nozaki S; Kitahara H; Ohara T; Kato K; Kawashiri S; Yamamoto E
Oncol Rep; 2007 Oct; 18(4):987-91. PubMed ID: 17786364
[TBL] [Abstract][Full Text] [Related]
3. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a chemoresistance marker in human oral squamous cell carcinoma treated with cisplatin.
Miyashita H; Nitta Y; Mori S; Kanzaki A; Nakayama K; Terada K; Sugiyama T; Kawamura H; Sato A; Morikawa H; Motegi K; Takebayashi Y
Oral Oncol; 2003 Feb; 39(2):157-62. PubMed ID: 12509969
[TBL] [Abstract][Full Text] [Related]
4. Role of Na+, K+-ATPase alpha1 subunit in the intracellular accumulation of cisplatin.
Kishimoto S; Kawazoe Y; Ikeno M; Saitoh M; Nakano Y; Nishi Y; Fukushima S; Takeuchi Y
Cancer Chemother Pharmacol; 2006 Jan; 57(1):84-90. PubMed ID: 16044341
[TBL] [Abstract][Full Text] [Related]
5. Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells.
Kalayda GV; Wagner CH; Buss I; Reedijk J; Jaehde U
BMC Cancer; 2008 Jun; 8():175. PubMed ID: 18565219
[TBL] [Abstract][Full Text] [Related]
6. Sensitization of cancer cells towards Cisplatin and Carboplatin by protein kinase D inhibitors through modulation of ATP7A/B (copper transport ATPases).
Janardhanan P; Somasundaran AK; Balakrishnan AJ; Pilankatta R
Cancer Treat Res Commun; 2022; 32():100613. PubMed ID: 35908410
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.
Samimi G; Safaei R; Katano K; Holzer AK; Rochdi M; Tomioka M; Goodman M; Howell SB
Clin Cancer Res; 2004 Jul; 10(14):4661-9. PubMed ID: 15269138
[TBL] [Abstract][Full Text] [Related]
8. Effect of copper and role of the copper transporters ATP7A and CTR1 in intracellular accumulation of cisplatin.
Matsumoto S; Tanaka T; Kurokawa H; Matsuno K; Hayashida Y; Takahashi T
Anticancer Res; 2007; 27(4B):2209-16. PubMed ID: 17695505
[TBL] [Abstract][Full Text] [Related]
9. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance.
Komatsu M; Sumizawa T; Mutoh M; Chen ZS; Terada K; Furukawa T; Yang XL; Gao H; Miura N; Sugiyama T; Akiyama S
Cancer Res; 2000 Mar; 60(5):1312-6. PubMed ID: 10728692
[TBL] [Abstract][Full Text] [Related]
10. Sec61β controls sensitivity to platinum-containing chemotherapeutic agents through modulation of the copper-transporting ATPase ATP7A.
Abada PB; Larson CA; Manorek G; Adams P; Howell SB
Mol Pharmacol; 2012 Sep; 82(3):510-20. PubMed ID: 22710939
[TBL] [Abstract][Full Text] [Related]
11. Copper transport systems are involved in multidrug resistance and drug transport.
Furukawa T; Komatsu M; Ikeda R; Tsujikawa K; Akiyama S
Curr Med Chem; 2008; 15(30):3268-78. PubMed ID: 19075668
[TBL] [Abstract][Full Text] [Related]
12. miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A).
Song L; Li Y; Li W; Wu S; Li Z
J Cell Biochem; 2014 Jul; 115(7):1234-42. PubMed ID: 24038379
[TBL] [Abstract][Full Text] [Related]
13. Functional interactions of Cu-ATPase ATP7B with cisplatin and the role of ATP7B in the resistance of cells to the drug.
Leonhardt K; Gebhardt R; Mössner J; Lutsenko S; Huster D
J Biol Chem; 2009 Mar; 284(12):7793-802. PubMed ID: 19141620
[TBL] [Abstract][Full Text] [Related]
14. Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer.
Owatari S; Akune S; Komatsu M; Ikeda R; Firth SD; Che XF; Yamamoto M; Tsujikawa K; Kitazono M; Ishizawa T; Takeuchi T; Aikou T; Mercer JF; Akiyama S; Furukawa T
Cancer Res; 2007 May; 67(10):4860-8. PubMed ID: 17510416
[TBL] [Abstract][Full Text] [Related]
15. Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells.
Katano K; Safaei R; Samimi G; Holzer A; Tomioka M; Goodman M; Howell SB
Clin Cancer Res; 2004 Jul; 10(13):4578-88. PubMed ID: 15240550
[TBL] [Abstract][Full Text] [Related]
16. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
Samimi G; Howell SB
Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
[TBL] [Abstract][Full Text] [Related]
17. The CXXC motifs in the metal binding domains are required for ATP7B to mediate resistance to cisplatin.
Safaei R; Adams PL; Maktabi MH; Mathews RA; Howell SB
J Inorg Biochem; 2012 May; 110():8-17. PubMed ID: 22459168
[TBL] [Abstract][Full Text] [Related]
18. Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells.
Beretta GL; Gatti L; Tinelli S; Corna E; Colangelo D; Zunino F; Perego P
Biochem Pharmacol; 2004 Jul; 68(2):283-91. PubMed ID: 15194000
[TBL] [Abstract][Full Text] [Related]
19. Vitamin B6 metabolism influences the intracellular accumulation of cisplatin.
Galluzzi L; Marsili S; Vitale I; Senovilla L; Michels J; Garcia P; Vacchelli E; Chatelut E; Castedo M; Kroemer G
Cell Cycle; 2013 Feb; 12(3):417-21. PubMed ID: 23287530
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of tumor resistance to cisplatin mediated by the copper transporter ATP7B.
Dmitriev OY
Biochem Cell Biol; 2011 Apr; 89(2):138-47. PubMed ID: 21455266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
